The NHS will last as long as their are folk left to fight for it
Today your junior doctors were those folk✌️
Proud of my colleagues
#JuniorDoctorsStrike
🙏Thank you @Uroweb#EAU23 for the BEST PAPER ON FUNDAMENTAL RESEARCH AWARD @Cancer_Cell https://t.co/wqQfDTJlR1 (Open Access)🎉
Importantly, this is recognition for the huge team effort @royalmarsdenNHS @TurajlicLab @TheCrick@uclcancer & others 🙌over many yrs
Truly grateful.
New position available to join @NickyMcGranahan Lab at UCL. Seeking collaborative and self-motivated Research Fellow to work on cancer evolution - deciphering impact of treatment on acquisition of somatic alterations and immune microenvironment. ℹ️ https://t.co/rlIlBZJYFU
📢We discussed updates on the AUDURA trial investigating adjuvant osimertinib in patients with resected EGFRm stage IB–IIIA #NSCLC with @DrSanjayPopat at #ESMO22!
🎥Interview coming soon to https://t.co/ys1d8pDAKO - watch this space!
@myESMO#LungCancer#LCsm#TrialUpdate#CTSM
Exciting indeed! Thank u for allowing @SWOG @NCICTEP_ClinRes to present results of #S1801 Improvement in event-free survival in #Neoadjuvant regimen of pembro 200mg q3wk➡️ surgery ➡️15 doses of pembro compared to surgery ➡️ 18 adjuvant doses of pembro in resectable melanoma
@MyriamChalabi@HazelOSulliva14@myESMO Thanks lovely Myriam! It was so so wonderful seeing you again! Also very lovely to see @lab_kok and the rest of the NKI crew. Really missed you and hope to see you again soon! Please come visit when in London!
NOW we must change the #melanoma management guidelines across the world. #Neoadjuvant#immunotherapy better than adjuvant in resectable stage 3&4 melanoma SWOG1801 HR 0.58 p0.004 fir event-free survial
At #EONS15LUNG symposium ‘We are raising awareness of inequities re access to lung cancer treatment and care and improving lung cancer prevention, early detection, treatment and care,’ says speaker @nurseygerty #EONS15#ESMO22@KarabaticSandra@JoVick13@silvija_p20 @JanssenUK
Great discussion of the immunotherapy abstracts by Dr. @drMaryOBr - note the delayed separation of survival curves with POSEIDON. We've seen similar patterns in other studies. #ESMO22
ADAURA updated results nicely challenged by @DrSanjayPopat regarding the slope steepness in each stage. "curative" effect in early stage, "delaying" effect in 2/3 stages ? #ESMO22@OncoAlert
Congratulations Joyciline Jepkosgei on the fantastic run to win the #LondonMarathon. We are proud of you for flying our flag high. 🇰🇪
Well in!
Keep running and keep inspiring our upcoming athletes. Hongera!
Opposing roles of the immune system in tumors. Would this explain why some tumors have dramatic responses versus other Hyperprogression ? Fascinating @ScienceMagazine@weldeiry@Dr_R_Kurzrock https://t.co/221tCwKMcU